Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Zacks Analyst Blog Highlights: Isis Pharmaceuticals, Inc., Schering-Plough Corp., Sara Lee Corp., EnCana Corp. and Euroseas Ltd
- CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), Schering-Plough Corp. (NYSE: SGP), Sara Lee...
- Research articles 2008-09-24
- Regulus Therapeutics and Collaborators Publish New Data on a Critical Role for miR-21 in Brain Tumors
- CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the publication of new research in the journal Molecular and Cellular Biology on the role of...
- Research articles 2008-08-19
- Alnylam Awarded Continued Funding Under U.S. Government Contract to Develop RNAi Therapeutics for Biological Threats
- Commitment for Continued Funding of $7.5 Million Supports Alnylam Biodefense[TM] Efforts and Broad Technology Development CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that the National Institute of Allergy and Infectious Diseases NIAID, a component of the National Institutes of Health NIH,...
- Research articles 2008-08-06
- Regulus Therapeutics Selected for Fierce 15 Top Biotech Companies
- CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA miRNA therapeutics, announced today that it has been named to the annual FierceBiotech "Fierce 15" list, designating it as...
- Research articles 2008-06-24
- We may all be space aliens: study
- PARIS AFP — Genetic material from outer space found in a meteorite in Australia may well have played a key role in the origin of life on Earth, according to a study to be published Sunday. European and US scientists have proved for the first time that two bits...
- Research articles 2008-06-13
- The ABCs of molecular genetics
- Dear Dr. SerVaas, I consider myself an educated reader, but I have forgotten the basics about genes and how RNA differs from DNA, Could you address this in basic language? Donald Ray Indianapolis, Indiana Molecular biologists explain it this way: DNA makes RNA, RNA makes protein,...
- Research articles 2008-05-01
- Intradigm Strengthens RNA Interference (RNAi) Position with MIT License.
- Intradigm Corporation (Palo Alto, CA), a leading developer of targeted, systemic RNA interference RNAi therapeutics, announced that it has licensed a key patent related to nucleic acid delivery technologies in the field of RNAi drug development from Massachusetts Institute of Technology (Cambridge, MA). The licensing of...
- Research articles 2008-02-01
- Synamatix will collaborate with the Emory University School of Medicine
- Synamatix will collaborate with the Emory University School of Medicine to analyze small RNAs generated from mouse brain cognitive disease studies.
- Research articles 2008-01-31
- News For The Morning.
- M2 PRESSWIRE-18 January 2008-Stock Profiler.US: News For The MorningC1994-2008 M2 COMMUNICATIONS LTD RDATE:18012008 New York, NY -- StockProfilers' "Stock News" For this Friday: Planar Systems, Inc. (NASDAQ: PLNR); Metavante Technologies, Inc. (NYSE: MV); Kintera Inc....
- Research articles 2008-01-18
- RealPennies.com: Turning Pennies into dollars: (OTC BB:EWIN), (Nasdaq: GNTA), (OTC BB:EFSF) , (NASDAQ: RIMM), (NASDAQ: INTC).
- M2 PRESSWIRE-18 January 2008-RealPennies.com: RealPennies.com: Turning Pennies into dollars: (OTC BB:EWIN), (Nasdaq: GNTA), (OTC BB:EFSF) , (NASDAQ: RIMM), (NASDAQ: INTC).C1994-2008 M2 COMMUNICATIONS LTD RDATE:18012008 Are you a public company looking for exposure? Contact RealPennies.com - 1.800.940.6559 ...
- Research articles 2008-01-18
- Speak with other shareholders about: (NASDAQ: PLNR), (NYSE: MV), (NASDAQ: KNTA), (Nasdaq: YHOO), (Nasdaq: SMTC), (NASDAQ: IVGN).
- M2 PRESSWIRE-18 January 2008-Stockwire.com: Speak with other shareholders about: (NASDAQ: PLNR), (NYSE: MV), (NASDAQ: KNTA), (Nasdaq: YHOO), (Nasdaq: SMTC), (NASDAQ: IVGN)C1994-2008 M2 COMMUNICATIONS LTD RDATE:18012008 AUSTIN, TX -- Are you looking to speak with other investors about your favorite...
- Research articles 2008-01-18
- EWIN Ready To Launch Online Gaming Platform In China.
- M2 PRESSWIRE-17 January 2008-AnalystResearchReport.com: EWIN Ready To Launch Online Gaming Platform In ChinaC1994-2008 M2 COMMUNICATIONS LTD RDATE:17012008 Stocks to Watch: eWorld Interactive, Inc. (OTC BB:EWIN),Genta Incorporated (Nasdaq: GNTA), eFoodSafety.com (OTC BB:EFSF) , Obopay, Inc. (NASDAQ: RIMM) Intel Corporation...
- Research articles 2008-01-17
- Michael J. Fox Foundation Commits up to $3.8 Million to Develop Gene Silencing Neuroprotective Treatment for Parkinson's Disease
- To: NATIONAL EDITORS Contact: Media: Holly Barkhymer, +1-212-509-0995 x242, hbarkhymer@michaeljfox.org, or Research: Todd Sherer, PhD, +1-212- 509-0995 x243, tsherer@michaeljfox.org NEW YORK,Jan. 4/PRNewswire-USNewswire/ --The Michael J. Fox Foundation has committed up to $3.8 million for the development of a gene silencing therapeutic to treat Parkinsons disease by reducing expression of...
- Research articles 2008-01-04
- Nastech Receives Notice of Allowance for United States Patent Related to Methods for Identifying Cell-Specific Targeting Peptides.
- Nastech Pharmaceutical Company, Inc. (Bothell, WA) announced that the United States Patent and Trademark Office USPTO has issued a Notice of Allowance for United States patent application 10/976,942, entitled "Phage Displayed Trp Cage Ligands." The patent application has claims that relate to a novel, high-throughput method...
- Research articles 2008-01-01
- New Technique Involving Roche's LightCycler® 480 Instrument Enables Efficient and Economic Studies on RNA Editing
- PENZBERG, Germany -- Current research in the area of RNA editing is limited by the lack of cheap, effective approaches for screening for new editing sites or for mutants affected in the editing process. Previously used methods to study RNA editing, such as cDNA sequencing, primer extension or pyrosequencing are...
- Research articles 2008-03-04
- Criticality of micro RNAs in Functional Genomics Heightens micro RNA R&D
- PALO ALTO, Calif. -- Researchers and companies worldwide have realized the importance of RNA interference RNAi as a novel tool for analyzing gene function and identifying new drug targets and target validation. The overwhelming information in hand about the existence of miRNAs with unique functions has created intriguing possibilities for...
- Research articles 2007-11-06
- New anti-HIV drug 'promising' say researchers
- PARIS AFP — A prototype drug, tested on lab-dish samples of the AIDS virus, has shown great promise in attacking HIV from an unprecedented direction, French researchers reported on Friday. The drug inhibits the human immunodeficiency virus HIV at a key point -- when it uses the hijacked machinery...
- Research articles 2007-10-25
- External RNA Controls Consortium Announces Approximately 100 Controls Have Entered Final Testing Phase
- SANTA CLARA, Calif. -- The External RNA Controls Consortium ERCC announced today that approximately 100 of the selected external RNA controls are now in the final testing phase, which will be completed by the end of 2007. Once the phase is complete, The National Institute of Standards and Technology NIST...
- Research articles 2007-06-15
- Alnylam Pharmaceuticals Reports First Quarter 2007 Financial Results
- - Product Pipeline, Revenues and Cash Position Significantly Strengthened Year-Over-Year - CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the quarter ended March 31, 2007 and company highlights. "We have made important advancements already this year,...
- Research articles 2007-05-09
- CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
- LOS ANGELES -- CytRx Corporation (NASDAQ:CYTR) today announced that the RNA interference RNAi delivery technology exclusively licensed to its majority-owned subsidiary, RXi Pharmaceuticals Corporation RXi, has been published in the April 2007 issue of peer-reviewed scientific journal ACS Chemical Biology. The technology was developed by RXi Co-founder, Scientific Advisory Board...
- Research articles 2007-04-23
- << Previous
- page 1 of 7
- Next >>
Refining Tags
- Biotechnology (105 results)
- DNA (28 results)
- Nasdaq Stock Market Inc. (16 results)
- SECURITY (15 results)
- Cell (15 results)
- Yale University (15 results)
- protein (14 results)
- Alnylam Pharmaceuticals Inc. (13 results)
- Company (12 results)
- patent (12 results)
- stock (11 results)
- FINANCE (11 results)
- virus (11 results)
- Investment (10 results)
- Massachusetts Institute of Technology (10 results)
- scientist (10 results)
- researcher (10 results)
- Gene (9 results)
- Molecule (8 results)
- biology (7 results)
- Invitrogen Corp. (6 results)
- HEALTHCARE (4 results)
- European Patent Office (4 results)
- collaboration (4 results)
- Isis Pharmaceuticals Inc. (4 results)
- Molecular Inc. (4 results)
- Dr. (4 results)
- University of Massachusetts (4 results)
- BioMed Central (4 results)
- Stanford University (4 results)
- PRODUCTIVITY (4 results)
- wireless (4 results)
- Agilent Technologies Inc. (4 results)
- genome (4 results)
- National Science Foundation (4 results)
- Agence France-Presse (3 results)
- HARDWARE (3 results)
- NYSE Euronext (3 results)
- Affymetrix (3 results)
- technique (3 results)
- monitoring (3 results)
- FDA (3 results)
- therapy (3 results)
- tool (3 results)
- Harvard University (3 results)
- mouse (3 results)
- SOFTWARE (3 results)
- Baltimore (3 results)
- professor (3 results)
- U.S. Patent and Trademark Office (3 results)
